Listen to Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address key questions on the use of CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer treatment. The discussion covers genomic testing options, adjuvant treatment duration, toxicity management topics, and how the available clinical data and updated guidelines influence therapeutic decisions.

Listen to Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the diagnosis, prognosis, and current limited treatment options for poorly differentiated extrapulmonary neuroendocrine carcinomas, followed by a discussion focusing on emerging DLL3-targeted therapies, including bispecific therapies, antibody–drug conjugates, and CAR T-cell therapies, and their potential roles in improving patient outcomes.

Listen to this podcast with clinical and managed care pharmacy expert perspectives on the use of available and emerging subcutaneous immunotherapy options for patients with cancer

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, discuss their thoughts on a few of the most impactful studies in lymphomas and acute lymphoblastic leukemia (ALL) from the EHA and ICML 2025 congresses.

In this podcast, experts discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting.

Audio podcast with expert insights and takeaways from a large educational program on available and emerging first-line treatment options for HER2-positive metastatic breast cancer.

In this episode, Eytan M. Stein, MD, and Eunice S. Wang, MD, explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care.

In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP explore the latest key clinical updates on BTK inhibitors in CLL, featuring insights from the randomized phase III FLAIR, SEQUOIA, and BRUIN CLL-321 trials presented at ASCO and EHA 2025. This episode unpacks evolving treatment strategies, MRD-guided approaches, and what these developments mean for oncology professionals.

Listen to this audio podcast with expert insights and overview of the latest data for immune checkpoint inhibitors for advanced or metastatic hepatocellular carcinoma (HCC), for intermediate HCC in combination with TACE, and the latest guidelines for high-risk early HCC.

In this podcast, experts discuss the latest frontline treatment options for advanced Hodgkin lymphoma and approaches to personalizing treatment for the general patient population, older patients, and pediatric patients.

In this podcast, experts discuss CELMoD therapy for multiple myeloma, including mechanism of action, available clinical data and ongoing trials, and future implications.

Description: A brief 1-2 sentences that summarizes the content. It is displayed on the activity page and podcast channel page. This should not mention certification of the activity. Include faculty names whenever possible for promotional name recognition and improved searchability. Include the SEO Primary Keyword/Keyword Phrase. Listen to Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities.

This podcast explores the role of HER2-targeted antibody–drug conjugates (ADCs), evolving safety considerations, and future directions across genitourinary, gastrointestinal, and gynecologic cancers.

This podcast explores the evolving role of HER2-targeted antibody–drug conjugates, exploring their mechanisms of action, and emerging clinical data across genitourinary, gastrointestinal, and gynecologic cancers.

An audio podcast with expert insights on the latest evidence on targeting B7-H3 in small cell lung cancer.

This podcast explores the expanding role of HER2-targeted ADCs across genitourinary, gastrointestinal, and gynecologic cancers. Experts discuss HER2 alterations, molecular testing strategies, and emerging clinical data.

Audio podcast with expert insights on the current treatment landscape for first-line management of HER2-positive metastatic breast cancer considering the latest available evidence.

Listen as experts discuss key clinical pearls and answer frequently asked questions on the use of CDK4/6 inhibitors for HR-positive/HER2-negative early and metastatic breast cancer in this podcast episode, including insights related to optimal sequencing and ensuring adherence to therapy.

Listen to this expert overview of the most interesting findings related to the clinical use of bispecific antibody therapy for relapsed/refractory multiple myeloma that were presented at the 2024 annual American Society of Hematology meeting.

Audio podcast with key highlights on current and emerging data for the use of oral SERDS in patients with HR+/HER2- ESR1-mutated advanced breast cancer. Listen to experts put new trial results into context and cover practical perspectives and takeaway points for your everyday practice.